Introduction
Urinary Tract Infections (UTI) are among the common diseases in the pediatric age group. The diagnosis of the disease is not always easy because of the variable clinical findings. Delays in diagnosis and treatment may lead to undesirable conditions such as renal scarring, hypertension, and chronic renal insufficiency. In order to minimize these problems, early diagnosis and effective treatment of the disease is necessary [1-3]. For this purpose, effective biomarkers are needed that will enable both early diagnosis of UTI and distinguish upper UTI from lower UTI. Therefore, levels of serum leukocytes (WBC), C-Reactive Protein (CRP), and Erythrocyte Sedimentation Rate (ESR) [4], and serum IL-6 [5] and NGAL [6,7] levels are currently being used.

Galectin-3 is a protein that plays a role in acute inflammation and is produced by macrophages, activated T cells, epithelial cells, and fibroblasts [8]. Galectin-3 activates NADPH-oxidase and increases the production of superoxide from neutrophils [9], increases macrophage chemotaxis and also increases the capacity for phagocytosis [10]. It also plays a role in the adhesion of neutrophils to the endothelium [11].

It has been shown in previous studies that high galectin-3 levels have protective effects against pneumonia caused by Gram (+) [11] and meningitis caused by Gram (-) [12] bacteria. However, there is no study about its role in the diagnosis of urinary tract infection. In this study, we aimed to test whether the galectin-3 molecule can be used in the diagnosis of UTI.

Material and Methods
The local Ethics Committee approved the study. Between September 2015 and September 2016, patients admitted to our pediatric clinic with findings suggesting a UTI diagnosis were included in the study. Included complaints at admission were fever, abdominal pain, vomiting, and side pain for upper UTI; and dysuria, suprapubic pain, pollakuria, and enuresis for lower UTI. Urine samples were taken from children under 2 years with sterile bags or probes, and from older children by mid-flow urine sample method. Blood was drawn for complete blood count, CRP, ESR, serum creatinine, IL-6, NGAL, and galectin-3 levels. Hemogram and other biochemical tests were

Material and Methods
The local Ethics Committee approved the study. Between September 2015 and September 2016, patients admitted to our pediatric clinic with findings suggesting a UTI diagnosis were included in the study. Included complaints at admission were fever, abdominal pain, vomiting, and side pain for upper UTI; and dysuria, suprapubic pain, pollakuria, and enuresis for lower UTI. Urine samples were taken from children under 2 years with sterile bags or probes, and from older children by mid-flow urine sample method. Blood was drawn for complete blood count, CRP, ESR, serum creatinine, IL-6, NGAL, and galectin-3 levels. Hemogram and other biochemical tests were
Statistical analysis was performed using SPSS 18.0 for Windows. The distribution of the parametric variables was assessed using the one-sample Kolmogorov–Smirnov test. Independent variables were compared with Student’s t-test for normally distributed data and Mann–Whitney U test for non-normally distributed data. Comparisons of categorical data were made using the Chi-square test. After correlation analysis was done, regression analyses were performed according to the categorical and nominal values of the groups, and ROC analysis was performed. Statistically significance was defined as p<0.05.

Results

The study included 30 patients with UTI and 30 healthy controls. Seventeen of the patients (56.6%) were female, and their mean age was 6.3 years (40 days-14 years). Of the control group, 12 (40%) were female, and their mean age was 7.8 years (3 months to 14 years). There were no significant differences in sex and age between the two groups (p=0.2, p=0.18, respectively).

Table 1: Comparison of patients with UTI and control group.

| Gr    | Group                  | n | Age, mean±SD (years) | Sex (female, %) | Galectin-3 (pg/ml) | NGAL (ng/ml) | IL-6 (ng/l) | CRP (mg/l) | ESR (mm/hour) | Total WBC count (µ/l) | ANC (µ/l) | ALC (µl) | NLR | Platelet (µ/l) | MPV (fl) | Urine pH | Urine density |
|-------|------------------------|---|----------------------|-----------------|-------------------|---------------|-------------|------------|--------------|----------------------|-----------|----------|-----|-------------|---------|----------|-------------|
| UTI (n=30) |                       |   | 6.3±4.5              | 56.6            | 147.5±62.1        | 131.9±71.3    | 100.8±67.4  | 28.2±51    | 17±13.3      | 9905±3464.4         | 5618.7±3971.9 | 3269.3±1786.8 | 2.7±2.8       | 312233±81448 | 7.6±1.7 | 5.6±0.9  | 1014.5±8.3   |
| Control (n=30) |                   |   | 7.8±4.1              | 40              | 111.3±56.8        | 97.2±50.3     | 82.2±39     | 1.9±2.8     | 8.3±3.9       | 7037.6±1807.5      | 3726±1443.9 | 2359.7±1083.4 | 1.8±2.8       | 287800±105794 | 7.7±1.3 | 5.4±0.9  | 1018.8±6.5    |

*p=Mann-Whitney U; ALC: Absolute Lymphocyte Count; ANC: Absolute Neutrophil Count; CRP: C-Reactive Protein; ESR: Erithrocyte Sedimentation Rate; MPV: Mean Platelet Volume; NGAL: Neutrophil Gelatinase-Associated Lipocalin; NLR: Neutrophil Lymphocyte Ratio; UTI: Urinary Tract Infection.

Table 2: Comparison of patients with upper and lower UTI.

| Gr    | Group                  | n | Age, mean±SD (years) | Sex (female, %) | Galectin-3 (pg/ml) | NGAL (ng/ml) | IL-6 (ng/l) | CRP (mg/l) | ESR (mm/hour) | Total WBC count (µ/l) | ANC (µ/l) | ALC (µl) | NLR | Platelet (µ/l) | MPV (fl) | Urine pH | Urine density |
|-------|------------------------|---|----------------------|-----------------|-------------------|---------------|-------------|------------|--------------|----------------------|-----------|----------|-----|-------------|---------|----------|-------------|
| Upper UTI (n=8) |                  |   | 7.9±3.4              | 50              | 185.3±60.7        | 171.9±77.3    | 145.1±59    | 95.8±58     | 32.9±15.5     | 12941.3±4735.8         | 8801.8±2076.4 | 320233±81448 | 1.5±1.6       | 262250±70609 | 7.1±1.1 | 5.4±0.7  | 1017.5±6.5   |
| Lower UTI (n=22) |                 |   | 5.8±4.8              | 59              | 133.9±58          | 117.4±64.8    | 84.8±64     | 3.7±6.8     | 11.3±6        | 8801.8±2076.4         | 4074.5±2280.6 | 1338±1786.2 | 0.5±0.9       | 303040±8748 | 7.8±1.9 | 5.8±1.0  | 1013.4±8.8   |

*p=Mann-Whitney U; IL-6: Interleukin-6; NGAL: Neutrophil Gelatinase-Associated Lipocalin; WBC: White Blood Cell; CRP: C-Reactive Protein; MPV: Mean Platelet Volume; RDW: Red Cell Distribution Width; NLR: Neutrophil to Lymphocyte Ratio.

Citation: Bekdas M, Acar S, Erkocoglu M, Karabork S and Dilek M. Can Serum Galectin-3 Be used for Diagnosis of Childhood Urinary Tract Infections? SM J Urol. 2018; 4(1): 1039.

https://dx.doi.org/10.36876/smju.1039
determined that fever (75% versus 9%, p = 0.005) and costo-vertebral angle sensitivity (100% versus 0%, p = 0.003) were significantly higher in the patients with upper UTI. No statistically significant differences were found for other clinical findings (p > 0.05). When laboratory findings of the patients were examined, IL-6 (145±59 ng/L versus 84.8±64 ng/L, p = 0.01), total lymphocyte count (3747.3±1816.2 μL versus 1955.0±799.1 μL, p = 0.003), total neutrophil count (9865.0 ± 4633.3 μL versus 4074.5 ± 2280.6 μL, p = 0.001), CRP (95.8±58.8 mg/L versus 3.7±8.8 mg/L, p = 0.001), ESR (32.9±15.5 mm/h versus 11.3±6.0 mm/h, p < 0.001) and NLR (6.0±3.2 versus 1.5±1.6, p = 0.02) were significantly higher in the patients with upper UTI; there were no significant differences between other parameters (p < 0.05) (Table 2). Serum galectin-3 levels were significantly higher in the upper UTI group compared to lower UTI group (185.3±60.7 pg/ml versus 133.9±58 pg/ml, p = 0.02) (Figure 1).

A significant positive correlation was found in the patient group between serum galectin-3 level and IL-6 (r²=0.14, p = 0.01), serum galectin-3 level and NGAL (r=0.68, p = 0.001), serum galectin-3 level and CRP (r=0.4, p = 0.02), and serum galectin-3 level and ESR (r=0.38, p = 0.03).

We performed regression analyses for the factors affecting serum galectin-3 level in the study group. In the logistic regression analysis we performed, we found that fever (OR: 7.7 (95% CI: 1.1-52.1), p = 0.04) and vomiting (OR: 48.1, 95% CI: 1.8-1235.4, p = 0.02) have effects on serum galectin-3 levels. In the linear regression analysis, CRP (r²=0.14, p = 0.01), ESR (r²=0.18, p = 0.001), IL-6 (r²=0.5, p < 0.001) and NGAL (r²=0.88, p = 0.001) have effects on serum levels of galectin-3.

The Candida-growing case was excluded from the patient group, and the remaining microorganisms in the urine cultures of the remaining cases were classified as Gram (+) and Gram (-). According to this, while the galectin-3 level was 161.5 ± 61.4 pg/ml in Gram (-) cases, this value was 99.5 ± 22.3 pg/ml in Gram (+) cases. But the difference was not statistically significant (p = 0.057).

DMSA was performed in only 5 (62.5%) of the patients diagnosed with upper UTI, and renal scars were detected in only 2 (40%). While the level of galectin-3 was 217.7 ± 30.9 pg/ml in those with renal scar, this level was 122.9 ± 38.2 pg/ml in those without scar. The difference between these two groups was not statistically significant (p = 0.054).

ROC curves were made for serum galectin-3 levels on estimating upper UTI diagnosis. Serum galectin-3 was found to be able to diagnose upper UTI at a cut-off value of 130 pg/mL (p = 0.02) (Figure 2). Seven patients were diagnosed with upper UTI in this value resulting in an 87% sensitivity (specificity 68%) and a 93.7% negative predictive value (positive predictive value is 50%).

Discussion

UTI is among the most common diseases in the pediatric age group. Upper UTI patients often present with fever and tenderness on costavertebral angle as well as with abdominal pain and nausea/vomiting, whereas lower UTI patients have complaints of dysuria, enuresis, impingement sensation, and suprapubic tenderness [13]. Gram (-) bacteria are the most common causes of UTI; E. coli is found in most of these patients, and other genera include Klebsiella, Proteus, Enterobacter and Enterococci [13].

The levels of CRP in serum are increased in patients with UTI [14]. Cytokines such as IL-6 play an important role in this increase. IL-6, a pro-inflammatory cytokine produced during early inflammation, stimulates hepatocytes to increase fibrinogen and CRP production, resulting in increased fibrinogen and ESR [15-18].

NLR is a cheap and easily calculated index used to diagnose systemic inflammatory diseases [19,20]. It is accepted that NLR shows the severity of inflammation due to increased neutrophil production in bone marrow [21]. In our study, NLR was not beneficial in diagnosing UTI, but it was significantly higher in patients with upper UTI compared to lower UTI.

Serum levels of IL-6 [5] and NGAL [6,7] are also found to be increased in patients with UTI. In our study, we found that only NGAL is effective in diagnosing UTI. When we compared the patients with upper and lower UTI, we determined that serum levels of NGAL and IL-6 were significantly higher in the upper UTI patients compared to lower UTI patients, which is compatible with the literature [7,22].

Galectins play a key role in immunocyte homeostasis and inflammation [23,24]. Galectin-3, a member of this family, is an important proinflammatory cytokine. It has been shown that these cytokines secreted from monocytes and macrophages contribute to the regulation of natural and acquired immunologic responses by activating neutrophils and lymphocytes [10,11,23-25]. In our study,
we found that serum galectin-3 levels were significantly higher in patients with UTI compared to healthy subjects. Serum galectin-3 level is also found to be associated with the activity and severity of diseases with infectious and inflammatory presentations [26,27]. In our study, we also found that serum galectin-3 levels were significantly higher in upper UTI patients, which is a more severe presentation compared to the lower UTI. In addition, we found that serum galectin-3 alone could diagnose the upper UTI at a cut-off value of 130 (Sensitivity 87%, Specificity 68%, p=0.02). The sensitivity and negative predictive value of galectin-3 was higher in the upper UTI. These findings suggest that serum galectin level is a marker that can be used in the diagnosis of UTI infection and in the discrimination of upper and lower UTI, but additional work is needed in this regard.

Scar is a chronic inflammation that leads to tissue damage and eventual organ failure. Studies have shown that in the case of fibrosis, increased expression of galectin-3 induces collagen synthesis in fibroblasts [28,29]. Therefore, we expected serum galectin-3 levels to be higher in cases with renal scarring, but, although galectin-3 levels were high in the patients with renal scar, the difference was not statistically significant (p=0.054), which could be the result of the limited number of patients with scar in our study.

The microorganisms cultured in urine cultures were classified as Gram (+) and Gram (-). Galectin-3 level was found to be almost significantly higher in the Gram (-) group compared to the Gram (+) group (p=0.057); the main reason for this is the low number of UTI patients with Gram (+) origin. Larger scale studies are needed to determine the role of Galectin-3 in predicting the microorganism responsible for UTI.

There are studies showing a correlation between serum galectin-3 and CRP [30]. In our study, when the relationships between serum galectin-3 levels and other inflammatory markers were examined, we found a strong correlation with NGAL, weak correlations with IL-6 and CRP, and a weak correlation with ESR. We also found that CRP contributes 14%, ESR contributes 18%, IL-6 contributes 50%, and NGAL contributes 88% to increasing serum galectin-3 levels. These results indicate that serum galectin-3 may be a good marker for diagnosis in inflammation and infection.

The most important limitations of our study are that our work was done in a single center and with a small study population.

Conclusions

Serum galectin-3 may be an alternative to traditional serum inflammation markers both in diagnosing UTI and in the discrimination of upper and lower UTI. Serum galectin-3 discriminates the upper and lower UTI at a cut-off value of 130 and it has a positive correlation with markers such as CRP, ESR, IL-6 and NGAL, which are accepted as valid for upper UTI, strengthening our opinion that galectin-3 can be used to make the diagnosis of upper UTI.

References

1. Hansson S, Jodal U. Urinary tract infection. Pediatric nephrology 2004; 5:1007-1025.
2. Jantausch B, Kher K. Urinary tract infection. Clinical paediatric nephrology, 2nd edn. Informa UK, UK 2007; 553-73.
3. Jones K, Davison A, Cameron J. Urinary tract infection in infancy and childhood. Oxford Textbook of Clinical Nephrology. 2008; 2: 1261-1275.
4. Naseri M. Alterations of peripheral leukocyte count, erythrocyte sedimentation rate, and C-reactive protein in febrile urinary tract infection. Iran J Kidney Dis. 2008; 2: 137-142.
5. Masagis-Zagajewska A, Kumaitowa S, Wajdlich M. Utility of copeptin and standard inflammatory markers in the diagnostics of upper and lower urinary tract infections. BMC urol. 2015; 15: 1-5.
6. Yilmaz A, Sevketoğlu E, Gedikbasi A. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatric Nephrology. 2009; 24: 2387-2392.
7. Raffel A, Mohammadijafari H. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) might be an independent marker for anticipating scar formation in children with acute pyelonephritis. International Journal of Infectious Diseases. 2016; 45: 337-345.
8. Rabinovich GA, Baum LG, Tinari N. Galectin and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 2002; 23: 313-320.
9. Yamaoka A, Kuwabara I, Frigeri LG. Human lectin, galectin-3(epilson bp/ Mac-2), stimulates superoxide production by neutrophils. J Immunol. 1995; 154; 3479-3487.
10. Sano H, Hsu DK, Yu L. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol. 2000; 165: 2156-2164.
11. Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron MG. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol. 2002; 168: 1813-1822.
12. Quattroni P, Li Y, Lucchesi D, Lucas S, Hood DW, Herrmann M, et al. Galectin-3 binds Neisseria meningitidis and increases interaction with phagocytic cells. Cellular microbiology. 2012; 14: 1657-1675.
13. Elder JS. Urinary Tract Infections. In: Kliegman RM, Stanton BF, St Gemell JW, Schor NF. eds. Nelson Textbook of Pediatrics 20th ed. Philadelphia, PA: Elsevier Saunders. 2016: 2556-2562.
14. Bauer R, Kogan BA. New developments in the diagnosis and management of pediatric UTIs. Urologic Clinics of North America. 2008; 35: 47-58.
15. Benitez WE. Adjunct laboratory tests in the diagnosis of early-onset neonatal sepsis. Clinics in perinatology. 2010; 37: 421-38.
16. Amon S, Litmanovitz I. Diagnostic tests in neonatal sepsis. Current opinion in infectious diseases. 2008; 21: 223-227.
17. Lam HS, Ng PC. Biochemical markers of neonatal sepsis. Pathology. 2008; 40: 141-148.
18. Ng PC, Lam HS. Diagnostic markers for neonatal sepsis. Current opinion in pediatrics. 2006; 18: 125-131.
19. Pichler M, Hutterer G, Stoeckigt C, Chromecki T, Stojakovic T, Golbeck S, et al. Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. British journal of cancer. 2013; 108: 901-907.
20. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Herrmanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiology Biomarkers & Prevention. 2014; 23: 1204-1212.
21. Jilma B, Blann A, Pemerstorfer T, Stohlwawetz P, Eichler H-G, Vondrovce B, et al. Regulation of adhesion molecules during human endotoxemia: no acute effects of aspirin. American journal of respiratory and critical care medicine. 1999; 159: 857-863.
22. Chromek M, Tullus K, Hertting O, Jaremko G, Khalil A, Li Y-H, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediatric research. 2003; 53: 698-705.

Citation: Bekdas M, Acar S, Erkokcoglu M, Karabork S and Dilek M. Can Serum Galectin-3 Be used for Diagnosis of Childhood Urinary Tract Infections? SM J Urol. 2018; 4(1): 1039. https://dx.doi.org/10.36876/smju.1039
23. Cooper DN, Barondes SH. God must love galectins; they made so many of them. Glycobiology. 1999; 9: 979-84.

24. Liu FT. Galectins: a new family of regulators of inflammation. Clin Immuno. 2000; 97: 79-88.

25. Karlsson A, Follin P, Leffler H, Dahlgren C. Galectin-3 activates the NADPH oxidase in exudated but not peripheral blood neutrophils. Blood. 1998; 91: 3430-3438.

26. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. The Lancet. 2007; 369: 2196-2210.

27. Koca SS, Akbas F, Ozgen M, Yolbas S, Ilhan N, Gundogdu B, et al. Serum galectin-3 level in systemic sclerosis. Clin Rheumatol. 2014; 33: 215-220.

28. Kasper M, Hughes RC. Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. The Journal of pathology. 1996; 179: 309-316.

29. Hsu DK, Dowling CA, Jeng KCG, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. International journal of cancer. 1999; 81: 519-526.

30. Jin QH, Lou YF, Li TL, Chen HH, Liu Q, He XJ. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin Med J (Engl). 2013; 126: 2109-2115.